linjc16/ctgov huggingface dataset:
Early Outcomes of Radical Debridement Versus no Debridement Under Different Surgical Procedures

Study Overview
=================
Brief Summary
-----------------
Whether radical debridement is necessary for the treatment of thoracic and lumbar tuberculosis is still questionable. The objective of this prospective randomized study was to compare the outcomes of radical debridement versus no debridement under different surgical procedures for the treatment of thoracic and lumbar tuberculosis.

Detailed Description
-----------------
Seventy-four thoracic and lumbar tuberculosis patients with a neurological function of grade D and E underwent surgeries from January 2009 to January 2014. All patients were divided into group A and group B by taking the drawing of lots. In group A, radical debridement, bone graft and instrumentation were performed. In group B, isolated posterior instrumentation without debridement were performed in all cases and drainage of iliopsoas abscess via laparoscopy in 2 cases. The operative time, blood loss, visual analogue score (VAS), erythrocyte sedimentation rate (ESR), kyphotic angle, Frankel grading, fusion rate and complications were evaluated.

Official Title
-----------------
Outcomes of Radical Debridement Versus no Debridement Under Different Surgical Procedures for the Treatment of Thoracic and Lumbar Spinal Tuberculosis

Conditions
-----------------
Spinal Tuberculosis

Intervention / Treatment
-----------------
* Procedure: no debridement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Frankel grading was grade D and E Severe back pain Abscess combined with high pressure symptoms Larger sequestrum formation or sinus Significant spinal instability. Exclusion Criteria: Frankel grading was grade A,B and C Conservative treatment

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: spine surgery<br>The objective was to compare the outcomes of radical debridement versus no debridement under different surgical procedures for the treatment of thoracic and lumbar tuberculosis. | Procedure: no debridement<br>* It is a spinal surgery performed with isolated posterior instrumentation without debridement.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The operative time in minutes |  | 5 years | 
| blood loss in milliliter |  | 5 years | 
| erythrocyte sedimentation rate (ESR) in mm/h |  | 5 years | 
| kyphotic angle in degree |  | 5 years |
The Role of Ribose in Patients Diagnosed With Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
The purose of this research study is to determine the potential benefit of D-ribose, a nutritional supplement (a sugar), versus a placebo (another sugar) in people with fibromyalgia.

Detailed Description
-----------------
Two hundred to three hundred subjects (equally distribued between placebo and D-ribose) between 18-78 years of age will comprise this study. The final numbers enrolled will depend upon obtaining approximately 100 subjects that can display a high degree of compliance to TID dosing with approximately equal balance between the active and placebo arms.

Official Title
-----------------
The Role of D-RIbose in Patients Diagnosed With Fibromyalgia

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Dietary Supplement: D-ribose
* Other: dextrose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: previous diagnosis of fibromomyalgia by a MD Has been diagnosed with fibromyalgia and are over 18 years of age Does live in the United States Exclusion Criteria: does NOT have severe medication/chemical/supplement sensitivities does NOT have insulin dependent diabetes or other severe illnesses (cancer, hepatitis, congestive heart failure) does NOT have rheumatoid arthritis or gout previous use of ribose

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 78 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>D-ribose 5 grams TID orally | Dietary Supplement: D-ribose<br>* 5 grams administered orally TID<br>* Other names: Corvalen;|
| Placebo Comparator: 2<br>Dextrose 5 grams TID | Other: dextrose<br>* 5 grams orally TID<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Significant reduction in symptoms of pain and fatigue |  | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demonstrate an improvement in ones quality of life |  | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fibromyalgia, ribose, d-ribose, dextrose
Can Point of Care Chest Ultrasound Predicts Pulmonary Complications After Major Surgery?

Study Overview
=================
Brief Summary
-----------------
This study is done to estimate prevalence of the main detectable lung and cardiovascular complications by an ultrasound realized in room of post-interventional supervision at the patients whose duration of general anesthesia is superior at one hour after a surgery to risk

Official Title
-----------------
Can Point of Care Chest Ultrasound Predicts Pulmonary Complications After Major Surgery?

Conditions
-----------------
Intensive Care, Surgical

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physical status score > 1 Anesthesia of duration > 1 hour Visceral, orthopaedic, vascular, thoracic surgery, neurosurgery Exclusion Criteria: Technical incapacity of accessibility to the ultrasound window Cardiac or pulmonary transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiac and pulmonary functions | cardiac and pulmonary functions will be evaluated by cardiac and pulmonary ultrasound exams for all patient whom have a more than 1 hour surgical intervention | 1 hour |
Surgical Bleeding Control of Extra-corporeal Circulation (ECC) by Vacuum Devices

Study Overview
=================
Brief Summary
-----------------
the purpose of this study is to show that the vacuum control surgical bleeding helps stop bleeding extraMD (MD: Medical Device) at the orifice of the retrograde cannulation during a heart with Extra-corporeal circulation (ECC),

Conditions
-----------------
Bleeding

Intervention / Treatment
-----------------
* Procedure: cardiac surgery requiring ECC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: more or equal than 18 years old patient affiliated to social security or similarly regime patient sent to hospital for cardiac surgery requiring ECC Exclusion Criteria: Pregnant women and lactating mothers Ward of court or under guardianship Adult unable to express their consent Person deprived of freedom by judicial or administrative decision Person hospitalized without their consent Person under legal protection Person participating in another clinical study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: vacuum device - suction cup<br> | Procedure: cardiac surgery requiring ECC<br>* the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Persistence or absence of bleeding extraMD at the orifice of the retrograde cannulation when the suction cup is in place. |  | 20-30 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Persistence or absence of bleeding intraMD at the orifice of the retrograde cannulation when the suction cup is in place. |  | 20-30 min | 
| Persistence or absence of bleeding at the orifice of the retrograde cannulation when the vacuum was removed. |  | 20-30 min | 
| Persistence or absence of bleeding extraMD at the orifice of the aortic purge when the suction cup is in place. |  | 20- 30 min | 
| Persistence or absence of bleeding extraMD at the orifice of the aortic purge when the suction cup is in place. |  | 20 -30 min | 
| Persistence or absence of bleeding at the orifice of the aortic purge when the vacuum was removed. |  | 20 -30 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac surgery requiring ECC
Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed after first-line treatment

Official Title
-----------------
A Phase II, Open, Single-center Study of PD-1 Antibody and PARP Inhibitor as Consolidation Treatment for Patients With Extensive Stage Small Cell Lung Cancer Who Have Not Progressed After First-line Treatment

Conditions
-----------------
Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All subjects were required to sign the informed consent before starting the study; Histologically documented Extensive stage small cell lung cancer； ECOG PS 0 1 ； 18-75 years； According to recist1.1, CR or PR was achieved after 4-6 cycles of first-line etoposide and platinum chemotherapy; .Life expectancy ≥ 3 months； Exclusion Criteria: Recurrence or distant metastasis of localized small cell lung cancer after chemotherapy or concurrent chemoradiotherapy； Active infection including tuberculosis, HIV, hepatitis B and C； Interstitial pneumonia (ILD), drug-induced pneumonia, radiation-induced pneumonia requiring steroid therapy or active pneumonia with clinical symptoms, or other moderate to severe lung diseases that seriously affect lung function; Severe infection existed, including but not limited to infection complications, bacteremia, severe pneumonia, etc; Symptomatic brain metastasis and cancerous meningitis;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Camrelizumab+Fluzoparib<br> | Drug: Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors<br>* Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival (PFS) | To assess the efficacy of Camrelizumab and Fluzoparib combination therapy in terms of PFS | Approximately 3 years |
Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
Single-center registry of patients treated with at least one Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome at the Washington Hospital Center, with the aim of assessing clinical success and safety at 30 days, 6 months and annually for up to 3 years post Endeavor Stent implantation.

Detailed Description
-----------------
Interventional cardiology was revolutionized by the invention of stents, initially with the bare-metal stents (BMS) and recently with the drug-eluting stents (DES).Zotarolimus-eluting stents have shown promising results in randomized clinical trails, demonstrating a reduction of clinical and angiographic restenosis in comparison to BMS, and comparable clinically-driven target lesion revascularization rates in comparison with Sirolimus-eluting stents. While short-term and 1 year registry data is available from outside of the United States, it will be important to collect real-world data regarding the stent usage and outcomes in the United States. In this study we propose to follow patients who received at least one Endeavor® Stent as primary treatment for ACS for up to 3 years post initial stent implantation.

Official Title
-----------------
REWARDS-EMI (Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction)

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, male or female, >18 years of age Patients presenting with acute coronary syndrome (ACS), where ACS is defined as ST segment deviation of >1mm or an elevation of the isoenzymes greater than 2x upper limit of normal Patients who received at least one Endeavor drug-eluting stent at the Washington Hospital Center Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endeavor<br>Patients treated with at least 1 Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of Major Adverse Cardiac Events following implantation of at least one Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome |  | Follow Up |
In Vitro Maturation Induction of Oocytes From a Woman With Syndrome of Repeated Oocyte Maturation Failure in Vitro

Study Overview
=================
Brief Summary
-----------------
Donated oocytes is from a patient with repeated oocyte maturation failure in IVF cycles. Cytoplasm of matured metaphase II oocyte and active MPF were injected into the donated oocytes.

Detailed Description
-----------------
The study reported a woman with syndrome of repeated oocyte maturation failure where there is repeated production of immature oocytes.She underwent two IVF cycles in other hospital. All oocytes obtained were immature and the treatment were stopped.She underwent her third try in our hospital. The couple gave their informed consent: ICSI will be performed if maturation occurred, otherwise, the treatment would be stopped and the oocytes would be donated for study if the oocytes were not matured after 24 hours of culture. After ovarian hyperstimulation,14 oocytes were obtained. None of them was matured. The cycle was canceled and the oocytes were donated for study.To induce the immature oocytes in vitro, oocytes were 1)cultured in follicular fluid containing matured metaphase II oocyte; 2) performed intracytoplasmic sperm injection (ICSI) to induce intracellular Ca2+]i oscillations; 3)injected with active maturation promoting factor (MPF), 4)injected with cytoplasm of matured metaphase II oocyte.

Official Title
-----------------
The Factors Primarily Intrinsic to the Oocyte Are Responsible to the Oocyte Maturation Defective: a Case Report.

Conditions
-----------------
Oocyte Maturation Failure

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of syndrome of repeated oocyte maturation Exclusion Criteria: patients with matured oocytes in IVF cycles

Ages Eligible for Study
-----------------
Minimum Age: 32 Years
Maximum Age: 32 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| oocyte maturation failure<br>no intervention | Other: no intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oocyte nucleus maturation |  | April，2012 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
oocyte maturation failure, Maturation induction in vitro
Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

Study Overview
=================
Brief Summary
-----------------
This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.

Official Title
-----------------
A 4-week, Multicentre, Randomized, Double-blind, Double-dummy, Parallel Group Ambulatory Blood Pressure Monitoring Study to Investigate Whether Treatment With Lumiracoxib 100 mg Once Daily Results in an Improved 24-hour Blood Pressure Profile Compared to Ibuprofen 600 mg Three Times a Day in Osteoarthritis Patients With Controlled Hypertension

Conditions
-----------------
Osteoarthritis, Controlled Hypertension

Intervention / Treatment
-----------------
* Drug: lumiracoxib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Osteoarthritis of the hand, hip, knee or spine High blood pressure (<140/ 90 mmHg) which is controlled by antihypertensive medication(s). Exclusion criteria • Evidence or history of any cardiac and cerebral thrombotic/ ischemic diseases and/ or events Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: lumiracoxib|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the 24-hour systolic BP profile of lumiracoxib 100 mg o.d. in comparison to ibuprofen 600 mg t.i.d. after 4 weeks of treatment. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the effect of lumiracoxib 100 mg o.d. on diastolic BP derived from ABPM after 4 weeks of treatment in comparison to ibuprofen 600 mg t.i.d. |  |  | 
| Assessment of the effect of lumiracoxib 100 mg o.d. on daytime and nighttime BP (systolic and diastolic) derived from ABPM after 4 weeks of treatment in comparison to ibuprofen 600 mg t.i.d. |  |  | 
| Assessment of the effect of lumiracoxib 100 mg o.d. on the incidence of significant increases in ABP in comparison to ibuprofen 600 mg t.i.d. |  |  | 
| Exploratory analysis of the effect of lumiracoxib 100 mg o.d. on the incidence of uncontrolled hypertension in comparison to ibuprofen 600 mg t.i.d. |  |  | 
| Exploratory analysis of the effect of lumiracoxib 100 mg o.d. on the ABPM profile between 0 and 4 hours after morning dose in comparison to ibuprofen 600 mg t.i.d. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoarthritis,, hypertension,, lumiracoxib,, ibuprofen,, 24-hour blood pressure profile
Healthy Aging and Memory Study

Study Overview
=================
Brief Summary
-----------------
This project will focus on the development and testing of efficient, cost effective measures that are specifically designed for use in Alzheimer's Disease (AD) primary prevention trials.

Detailed Description
-----------------
This project will focus on the development and testing of efficient, cost effective measures that are specifically designed for use in AD primary prevention trials. The new or improved measures that have been developed will then be evaluated in 650 nondemented subjects enrolled in a simulated Alzheimer's disease prevention trial. Once enrolled, subjects will be followed for four years with annual clinical evaluations and interim six-month phone calls.

Official Title
-----------------
Alzheimer's Disease Prevention Instrument Protocol

Conditions
-----------------
Alzheimer Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 75 years or older. Fluent in English or Spanish. Stable medical condition for four weeks prior to screening visit. Stable medications for four weeks prior to screening visit. Either cognitively normal, or mild cognitive impairment. If MCI, the subject's CDR at screening have a global score of 0.5. mMMSE score greater than 88 for subjects with at least 8 years education, or greater than 80 for subjects with less than 8 years education, and FCSRT total free plus cued recall score greater than 44 with 3 learning trials. Willing to participate in four to five year follow-up study. Willing to identify person who can serve as informant. At least six years education or work history sufficient to exclude mental retardation Exclusion Criteria: Meets DSM IV criteria for dementia History of clinically significant medical illness that would interfere with participation in trial, including active malignancy, myocardial infarction, or cerebrovascular accident within the past year Alcohol or substance abuse and/or active major psychiatric disorders Concurrent participation in a clinical drug trial History of mental retardation

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention